Interleukin-6 Receptor (IL-6R) Expression in Human Gastric Carcinoma and its Clinical Significance

Simondurairaj, C; Krishnakumar, R.; Sundaram, Sandhya; Venkatraman, Ganesh

doi:10.1080/07357907.2019.1638395

Cited by 15 publications

(19 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-6 R can also be used as a prognostic marker in gastric cancer. Hence, IL-6 can be a potent therapeutic target for COVID-19 patients suffering from gastric cancer [ 68 ].…”

Section: Receptor-mediated Signaling With Gastrointestinal Disordersmentioning

confidence: 99%

“…IL-6 being a pro-inflammatory cytokine is linked to increased inflammation in chronic acute gastritis [ 89 , 90 ]. IL-6 may act as a prognostic marker for gastric cancer and a potential biomarker for COVID-19 progression [ 68 , 91 ]. Hence, tocilizumab and sarilumab are FDA-approved drugs which is an interleukin-6 receptor antagonist can be a potent therapeutic drug (Table 1 ) [ 92 , 93 ].…”

Section: Potential Colliding Targets and Associated Drugsmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Gastrointestinal Symptoms in COVID-19: a Molecular Approach

Sonkar

Kashyap

Varshney

et al. 2020

SN Compr. Clin. Med.

View full text Add to dashboard Cite

The pandemic of novel coronavirus disease (COVID-19) caused by the Severe Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) creates an immense menace to public health worldwide. Currently, the World Health Organization (WHO) has recognized the novel coronavirus as the main cause of global pandemic. Patients infected with this virus generally show fever, nausea, and respiratory illness, while some patients also manifest gastrointestinal symptoms such as abdominal pain, vomiting, and diarrhea. Traces of SARS-CoV-2 RNA have been found in gastrointestinal cells. Further angiotensin converting enzyme 2 (ACE2) the known receptor for the virus is extensively expressed in these cells. This implies that gastrointestinal tract can be infected and can also present them as a replication site for SARS-CoV-2, but since this infection may lead to multiple organ failure, therefore identification of another receptor is a plausible choice. This review aims to provide comprehensive information about probable receptors such as sialic acid and CD147 which may facilitate the virus entry. Several potential targets are mentioned which can be used as a therapeutic approach for COVID-19 and associated GI disorders. The gut microbiomes are responsible for high levels of interferon-gamma which causes hyper-inflammation and exacerbates the severity of the disease. Briefly, this article highlights the gut microbiome’s relation and provides potential diagnostic approaches like RDT and LC-MS for sensitive and specific identification of viral proteins. Altogether, this article reviews epidemiology, probable receptors and put forward the tentative ideas of the therapeutic targets and diagnostic methods for COVID-19 with gastrointestinal aspect of disease.

show abstract

“…IL-6 R can also be used as a prognostic marker in gastric cancer. Hence, IL-6 can be a potent therapeutic target for COVID-19 patients suffering from gastric cancer [ 68 ].…”

Section: Receptor-mediated Signaling With Gastrointestinal Disordersmentioning

confidence: 99%

Section: Potential Colliding Targets and Associated Drugsmentioning

confidence: 99%

Impact of Gastrointestinal Symptoms in COVID-19: a Molecular Approach

Sonkar

Kashyap

Varshney

et al. 2020

SN Compr. Clin. Med.

View full text Add to dashboard Cite

show abstract

“…It was previously identified that gastric carcinoma caused by Helicobacter pylori was closely associated with the immune response of the body (8,9). Moreover, cellular immunity dominated by cytokines was discovered to be involved in the occurrence of gastric carcinoma (10)(11)(12).…”

Section: Introductionmentioning

confidence: 99%

Apatinib inhibits gastric carcinoma development by regulating the expression levels of IL‑17 via the Bax/Bcl‑2 signaling pathway

2021

View full text Add to dashboard Cite

Gastric carcinoma is a common type of gastrointestinal tumor with high morbidity and mortality rates. IL-17 is a newly discovered cytokine that has been reported to serve an important role in the development of gastric carcinoma. The potential effect of apatinib on IL-17 expression levels in the development of gastric carcinoma has been rarely reported. The present study aimed to investigate the potential mechanism of IL-17 and apatinib in the development of gastric carcinoma. A total of 30 tumor and para-carcinoma tissues were collected from 30 patients with gastric carcinoma between January 2019 and December 2019 and the expression levels of IL-17 in the tissues were analyzed by reverse transcription-quantitative PCR and western blotting. An in vitro model of gastric carcinoma was also established using the HGC-27 cell line, in which the cells were divided into control, IL-17, IL-17-apatinib and apatinib groups. The expression levels of IL-17, Bax, Bcl-2 and caspase-3 were analyzed using reverse transcription-quantitative PCR and western blotting. An MTT assay and flow cytometry were used to analyze the proliferation and apoptosis of HGC-27 cells, respectively, and a Transwell assay was used to analyze the invasive ability of HGC-27 cells. The results revealed that the expression levels of IL-17 were significantly upregulated in the gastric carcinoma tissues compared with the para-carcinoma tissues. In vitro, IL-17 treatment promoted the proliferation and invasive ability of HGC-27 cells, but inhibited the apoptosis with the significantly downregulated expression levels of Bax and caspase-3 and the upregulated expression levels of Bcl-2 than control group. Conversely, apatinib treatment significantly inhibited the proliferative and invasive abilities of HGC-27 cells, but promoted cell apoptosis in the IL-17 and IL-17-apatinib groups.. Collectively, the present results suggested that the upregulation of IL-17 may be associated with the occurrence and development of gastric carcinoma. The findings indicated that apatinib may inhibit gastric carcinoma development by regulating IL-17 expression via the Bax/Bcl-2 signaling pathway. Therefore, the present findings may enhance the current knowledge of the effect of apatinib on gastric carcinoma cells.

show abstract

“…Furthermore, IL-6 receptor (IL-6R) expression has been reported in cancer cells. IL-6R expression in tissues has been reported to be significantly associated with invasion depth and lymph node metastasis in gastric cancer [12]. Moreover, IL-6R in tissues has been found to be a prognostic factor for survival in cervical cancer [13,14].…”

Section: Introductionmentioning

confidence: 99%

Expression of Interleukin-6 and the Interleukin-6 Receptor Predicts the Clinical Outcomes of Patients with Soft Tissue Sarcomas

Nakamura

Iino

et al. 2020

Cancers

View full text Add to dashboard Cite

Interleukin-6 (IL-6) affects the key parameters of oncogenesis, which increases the cell resistance to apoptosis, the proliferation of cancer cells, angiogenesis, invasion, malignancy, and the ability of tumor cells to respond to anticancer therapy. This study aimed to elucidate the association between IL-6 and IL-6 receptor (IL-6R) expression in tissues and clinical outcomes in patients with soft tissue sarcomas (STSs) because, to our knowledge, this has not been done before. We enrolled 86 patients with histologically-proven localized STSs who underwent surgical resection. The cohort included 48 men and 38 women, with a mean age of 65.6 years. The mean follow-up duration was 40.5 months. The expression of IL-6 and IL-6R was immunohistochemically determined. We analyzed prognostic factors for overall survival (OS) and metastasis-free survival (MFS). High IL-6 expression was observed in 23.3% (20/86), high IL-6R expression in 44.2% (38/86), and high expression of both in 16.3% (14/86) of patients. Multivariate analysis showed that a high expression of both IL-6 and IL-6R was a prognostic factor for OS and MFS. We found that this high expression indicated that the patient had a poor prognosis for OS and MFS.

show abstract

Interleukin-6 Receptor (IL-6R) Expression in Human Gastric Carcinoma and its Clinical Significance

Cited by 15 publications

References 23 publications

Impact of Gastrointestinal Symptoms in COVID-19: a Molecular Approach

Impact of Gastrointestinal Symptoms in COVID-19: a Molecular Approach

Apatinib inhibits gastric carcinoma development by regulating the expression levels of IL‑17 via the Bax/Bcl‑2 signaling pathway

Expression of Interleukin-6 and the Interleukin-6 Receptor Predicts the Clinical Outcomes of Patients with Soft Tissue Sarcomas

Contact Info

Product

Resources

About